Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Haemonetics (HAE) EPS (Weighted Average and Diluted) (2016 - 2025)

Haemonetics (HAE) has 17 years of EPS (Weighted Average and Diluted) data on record, last reported at $0.95 in Q4 2025.

  • For Q4 2025, EPS (Weighted Average and Diluted) rose 28.38% year-over-year to $0.95; the TTM value through Dec 2025 reached $3.63, up 42.91%, while the annual FY2025 figure was $3.31, 44.54% up from the prior year.
  • EPS (Weighted Average and Diluted) reached $0.95 in Q4 2025 per HAE's latest filing, up from $0.81 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at $1.17 in Q1 2025 and bottomed at -$0.22 in Q2 2021.
  • Average EPS (Weighted Average and Diluted) over 5 years is $0.55, with a median of $0.62 recorded in 2022.
  • Peak YoY movement for EPS (Weighted Average and Diluted): plummeted 164.71% in 2021, then surged 522.22% in 2022.
  • A 5-year view of EPS (Weighted Average and Diluted) shows it stood at $0.29 in 2021, then surged by 120.69% to $0.64 in 2022, then decreased by 4.69% to $0.61 in 2023, then increased by 21.31% to $0.74 in 2024, then grew by 28.38% to $0.95 in 2025.
  • Per Business Quant database, its latest 3 readings for EPS (Weighted Average and Diluted) were $0.95 in Q4 2025, $0.81 in Q3 2025, and $0.7 in Q2 2025.